<SEC-DOCUMENT>0001104659-19-029550.txt : 20190515
<SEC-HEADER>0001104659-19-029550.hdr.sgml : 20190515
<ACCEPTANCE-DATETIME>20190515081113
ACCESSION NUMBER:		0001104659-19-029550
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190514
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190515
DATE AS OF CHANGE:		20190515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		19825158

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a19-9979_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> May&nbsp;14, 2019</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">60 Jubilee Avenue, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 25.9pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (</font>&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="font-size:10.0pt;margin:0in .25in .0001pt 0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title&nbsp;of&nbsp;each&nbsp;class</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Trading&nbsp;Symbol</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which<br>   registered</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">American Depositary   Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAP</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Nasdaq Global   Select Market</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905632\19-9979-1\task9359245\9979-1-ba.htm',USER='C905632',CD='May 14 22:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Entry into a Material Definitive Agreement.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On May&nbsp;14, 2019, Adaptimmune Therapeutics plc </font>(the &#147;Company&#148; or &#147;Adaptimmune&#148;) entered into a collaboration and license agreement (the &#147;Collaboration Agreement&#148;) with </font>Alpine Immune Sciences,&nbsp;Inc. (&#147;Alpine&#148;), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, to develop next-generation SPEAR T-cell products which incorporate Alpine&#146;s secreted and transmembrane immunomodulatory protein (termed SIP&#153; and TIP&#153;) technology.&#160; The Company believes that this collaboration will further enhance its efforts to design and develop next-generation SPEAR T-cell therapies. Under the terms of the Collaboration Agreement, Adaptimmune will provide an upfront payment of $2 million to Alpine and research funding for ongoing programs.&#160; In addition, Alpine is eligible for downstream development and commercialization milestones of up to $288 million, if all pre-specified milestones for each program are achieved.&#160; Alpine is also eligible to receive low-single digit royalties on worldwide net sales of the applicable products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing summary of the material terms of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by the full text of the Collaboration Agreement, a copy of which will be filed as an exhibit to the Company&#146;s Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2019.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Events.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;15, 2019 the Company issued a press release announcing its entry into the Collaboration Agreement.&#160; The press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a19-9979_1ex99d1.htm#Exhibt99_1_095646" title="Click to goto ">Press   release dated May&nbsp;15, 2019.</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_220414_7928"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C905632\19-9979-1\task9359245\9979-1-ba.htm',USER='C905632',CD='May 14 22:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;15, 2019</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_220509_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C905632\19-9979-1\task9359245\9979-1-ba.htm',USER='C905632',CD='May 14 22:27 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a19-9979_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>






  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibt99_1_095646"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><img width="288" height="65" src="g99791mmi001.gif" alt="GRAPHIC"></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="335" height="64" src="g99791mmi002.gif"></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- </font></b>Adaptimmune to license Alpine&#146;s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses -</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">May&nbsp;15, 2019, Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences,&nbsp;Inc., </font>Seattle, WA</font>, (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced a collaboration and license agreement to develop next-generation SPEAR T-cell products which incorporate Alpine&#146;s secreted and transmembrane immunomodulatory protein (termed SIP&#153; and TIP&#153;) technology. This collaboration will further enhance Adaptimmune&#146;s efforts to design and develop next-generation SPEAR T-cell therapies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;</font>SPEAR T-cell therapies have demonstrated clinical promise for the treatment of solid tumors. Based on knowledge emerging from translational research of resistance mechanisms, we will start our first next-gen clinical study with ADP-A2M4CD8 in the second half of 2019,&#148; said Rafael Amado, Adaptimmune&#146;s President of R&amp;D. &#147;We are very excited to begin this collaboration with Alpine which complements our research on next-generation SPEAR T-cells. We believe that Alpine&#146;s platform technology could engage further rapid and flexible immunomodulatory mechanisms, which would enable the development of future next-generation SPEAR T-cells with enhanced antitumor potential.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Our directed evolution platform has successfully generated many unique, multi-functional protein domains designed to favorably modulate the tumor microenvironment via validated immune targets,&#148; said Stanford Peng, MD PhD, Alpine&#146;s President and Head of Research&nbsp;&amp; Development. &#147;We look forward to working with Adaptimmune to develop next-generation SPEAR T-cell therapies to achieve improved clinical outcomes.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alpine and Adaptimmune will collaborate on a specified number of programs to develop SIP and TIP candidates </font>with tailored affinities and modulatory activities that may enhance the anti-tumor responses seen with Adaptimmune&#146;s SPEAR T-cells.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For each program, Adaptimmune has an option to take a worldwide exclusive license for development and commercialization of SPEAR T-cell products incorporating the developed SIP or TIP candidate for the treatment of cancer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the collaboration agreement, Adaptimmune will provide an upfront payment and research funding for ongoing programs.&#160; In addition, Alpine may be eligible for downstream development and commercialization milestones up to $288M, if all pre-specified milestones for each program are achieved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alpine will receive low-single digit royalties on worldwide net sales of the applicable products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The Company&#146;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T</font>-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Alpine Immune Sciences,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alpine Immune Sciences,&nbsp;Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_215907_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\111376\19-9979-1\task9359590\9979-1-mm.htm',USER='111376',CD='May 15 02:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">improve patients&#146; lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation &#151; an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form&nbsp;10-Q filed with the Securities and Exchange Commission (SEC) on May&nbsp;6,&nbsp;2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements Alpine</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, Section&nbsp;21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the potential future development plans of our and our collaborators&#146; product candidates and our and our collaborators&#146; ability to successfully develop and achieve milestones in development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;intend,&#148; and other similar expressions among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators&#146; product candidates; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; our discovery-stage and pre-clinical programs may not advance into the clinic or result in approved products; any of our or our collaborators&#146; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Transmembrane Immunomodulatory Protein&#148;, &#147;TIP&#148;, &#147;Secreted Immunomodulatory Protein&#148;, &#147;SIP&#148; &#147;Variant Ig Domain&#148;, &#147;vIgD&#148;, and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences,&nbsp;Inc. in various jurisdictions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">S&#233;bastien Desprez &#151; VP, Communications and Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 1235 430 583</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_220001_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\111376\19-9979-1\task9359590\9979-1-mm.htm',USER='111376',CD='May 15 02:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +44 7718 453 176</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sebastien.Desprez@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D. &#151; Senior Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +1 215 825 9310</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +1 215 460 8920</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli.Miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Alpine Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pure Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Courtney Dugan, 212-257-6723</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cdugan@purecommunications.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pure Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jennifer Paganelli, 347-658-8290</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">jpaganelli@purecommunications.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_220025_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\111376\19-9979-1\task9359590\9979-1-mm.htm',USER='111376',CD='May 15 02:37 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g99791mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99791mmi001.gif
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M]O[^_@
M
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M@7]8M*8KWF('-RIAJP)9 PC%<)16I-$)G]HJ,9E@%H%X$*UMB(4KYLI 2X;
M 'YL$0<*T($$!$ !"K" #1I @ (TH !5VP@, E"!" 3   J(@ XJ$( $*,
M-^@&) T!@!#\$0\ @,'?[E  !4#@L0U00 \&D@T@.%9\!2C^@ YPLI%9%* '
MJRQ$!>XPBEE<H@<)Z&8W.@"$/^X" RJ8Q"PP88,(3$L@)K@!#!IABU%T0 4%
MF8$%$$J+1X"@ KP8R"Y D-Q:3$('&&C$'Q^A@$?8 @9W> @U,J #(Q91K$S8
M!#?DP 0E0*@@NW2"L+RC"C<F 0ZMF$,MF_"\;B"3- 1Q112;R00!=^*7TZR?
M' .HA"1X& G18>TV\YJ-$C1VG4$(GP)6H A#A* !,QB(#B)0 1-,P@\6J$ "
M3/"(0H0@ AWXFR(2 (.!] &S?]-#^$K "$%@ ,A_NX0!," %6O!"$"$H@!10
MF8@*S&"E&YE$ [J7C1X(8B FB._^1H* @4QR P\FZ!@W9F" YTXB KWXHQXP
MX+:!^.(&M+!D"8I,$!B 8$8E".4S'C*,M5FD$TKX(HN. <(FT.\H <YE)'T)
MJ238*H1(,.8QQVH95W!8#FWXI1+6T(8YMK4;QXAT !/HZ1 +Y(1X%30$.@"E
M:-Q@UXON!FFQ*Y ;&, $4H,!!)SK3@5T(-B** !V-^*' MC 7$INP$B[T0-@
MMZ@'!H#!,YHQC&@80@$A2"(O:!S>@9P@QJ@T2 GBVXUH<,"<V=#&B:31 #\,
M1 5J[JD*MMV,!%2RG0:9!0'PDXV&=\,6%<!/-QY!@+(AM1N8P%!%N(',)HSA
M&,LXAAC^)BC+  _8*-WP)1G7(#TWL,(H8YA@%B(,J<)$SY8+-HM*Y @I-83B
M$Z#X1)Y8&X(^WKH$#0#"1KBAAV-KMAMZ(, *!G*# A07DD$(['MFT8 .O"?:
M4Q>('JR=Y A80&J)B  '<,*+$M 8 Q; 0/AH++7)-&,&X"4="/R-N1#06Q<<
M(.<-Z$G.#N0A)RK@X97V*1!:*,"<,8R0 @1_@\'/H .*C\8=0A"$=CN$#PAH
M045BL81:)D$)LI8;BW22Z5XN 0K!I-Q!UI"_,5C&K"%L(C;$ ,!:9KB#UE1>
M@/A(8J0/8D8%. 'RP]X-'02@N-0&<L=JT75H2QOY-O@;']3^WC%&J!TGN_AQ
M=&>@3QT,?A@&:4;2+=F!,RMDW@*I10F: 8UFC+L9SM#W0%8@<:H#=!8)T&<(
MH0@5L OU9W_-$ W: !>\H (*H%X-D0TTX  5L@V3LQ#8X 8@Y 19$"IBD 5?
MI 1V@&F]QPFA  HH6#<J46# !%9%- ;Y,W,#@7M), <"$0LCYWNO]E9)0 ?6
ML S+P S3H$=%UTTEUF\#D0<&H'QB5P#,IP.W-2/<UWC>U@V-X&SOT0-1*!!^
M &3!Q@@0L'9O 5PWH!/:T OEPPOF-!F#IA,P$':K81GPUPW0$ *0QUJ7H$C<
ML (K]18V %"^T !"I T;48CU4PO^"B R!-$,EX!P5,>$#-$'$X  A$ 1K:!J
M=H -V8 -V& -<@!%&U0_Q!1""N1I;E _+(@$6X4E:T!&$>0$^&.# C$-<A-
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M##!@ H+0"(F@ AVPERI ESEA \+5#5)0 5+0"(R@!QT  WAS=R4@"#T& R>
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H!!NOAF,-*B$7"/ D#5NQK)4##I "4&JQZ[H+E#"L'!NR(CLR 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g99791mmi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99791mmi002.gif
M1TE&.#=A3P%  '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MZ2SQXO..9U^&IIZZ^_?P#VX]<$!#Z8$"NA#U_!F1AH7EQ>)6 @DLPD5L. &
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M&J1=F%YNA>$ ,W_/6UG4P\M0^--3C?BPC#.*'[&',A2V_ _1KX\_F0ZPS]8
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M#FP>(+Q0"C!3@U10=Z9Z0D31)0==*4J08NH 1'@J!_PH:\(TD-],%>PK(1M
M?]^5* &$3@G_ZR,BN!LB:LGT*/H" #1V6+N8A0:[A>% NY(@GBYT!GH@_(V:
MP$* R6)5PX U\,)")D+'#H1LF>H"?B$G3((99;07Q::S"":8G&: *Y+MQ]M\
M:*5(N-9?I&T7]#1PI-# 5$F#T9>P%*0/MEKYNL+A!U6M! W\,HQA(?/B8F_Y
MG1U 4/\ D+-6)%(U(*2!I "K6$QR-@: IHC+-;&!P&QP>)K'T1<M'PM+M$8I
M  *[=IB&[0=K1W0 #H2&7K0IP ZOAX@(1(*K'V[3 637CW,RMF#],D _>, V
MLV4W84<B8-UX.IQ1:]@!+3; 2OA%JOQ.E3Y7"Y%D#<"!G88&$1,X %<3N(^D
M!"42WPEG(L,):C4]CYV8^G$_5GO=J=JIJI;T'X<<"LD^,HL5'!* WKZZ[,[9
MD]L$^^HNZ:+N"0O'OSH&X[')&2,."/G,6(W)-:V%LA<*Y&<$W$$BF)H &PG$
M8DL=%,4 )RC8" \B"AC?BS-CW0%$@*4@99T_).O9K^&J"SC_:Q.F2+6UY2%"
MHQ-%  8TTX5PRQ2"?:067#OC6?N41C/]8-N2.(( #J"\,P-X23MST$XB<2!#
M 2!,%US[U;X9X&N^W0R0.@TY_V*=I#]#V<PNQ+^]]B/FZ\299$57PI<\JNCZ
MN6ZS\PEM!RC9OH995@"@+!1J;=;J6&\T7?_!,'1B1@!=OAZQ$=T=$&G-(!\#
MT;FCMSQ^,.NKBG6P@OV2CR]P8>&.T:,S#L$BML#F1C3Y_":<PF<F,_DYO/8O
MWNA"91Z.NI;R]8L(85(;CV%S320"&P<*,)>.(:#48IF+'R<+8;*4F]=A4:Q
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M"##A57UF\?XF90XDPJ1_Q25!QW$>>42^I.<4XQ)ZYK\3.FP1:#GS$1SD  %
MX$""S@@>1)A0(0 ! A$HS'"PX4**% U6Q)A1(\:)%3LF1(!("0$E$0Q FR@
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MV^<86"415SIPP9F+%%E@@9\V:-[T#6*)'T0(5L&?(AYP"'7U:0$=0-:H(+"
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1[O64LLUK:FTI66L#.A(0 #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
